Cerca Biotech

Executive Summary

Cerca Biotech is a German molecular diagnostics company specializing in women's health, with a focus on oncology and obstetrics. The company commercializes two key products: MammaTyper®, a breast cancer subtyping assay, and RNXtract®, an RNA purification kit for FFPE samples. As the European subsidiary of Shuwen Biotech, Cerca leverages its parent company's technology to access and distribute advanced diagnostics across Europe. Founded in 2018 and headquartered in Hamburg, the company operates in the competitive diagnostics sector with a clear niche in women's oncology. While currently in a private stage with limited public financial data, Cerca Biotech's established product portfolio and backing from Shuwen Biotech provide a foundation for growth. The company is well-positioned to capitalize on increasing demand for precision diagnostics, particularly in breast cancer subtyping and RNA-based testing. However, the lack of disclosed funding and early-stage status suggest that near-term commercial traction and strategic partnerships will be critical for valuation. Overall, Cerca Biotech represents a focused player in molecular diagnostics with potential for expansion in the European market, pending regulatory milestones and commercial execution.

Upcoming Catalysts (preview)

• Q3 2026CE-IVDR certification for MammaTyper assay70% success
• Q4 2026Launch of new liquid biopsy test for ovarian cancer50% success
• Q3 2026Partnership with a major European hospital network for distribution60% success